2018 Fiscal Year Final Research Report
Analysis of molecular factor to influence of immuno-checkpoint inhibitor in lung cancer treatment
| Project/Area Number |
16K09548
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Kyoto Prefectural University of Medicine |
|---|
Principal Investigator |
Takayama Koichi 京都府立医科大学, 医学(系)研究科(研究院), 教授 (50274444)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
井上 匡美 京都府立医科大学, 医学(系)研究科(研究院), 教授 (10379232)
金子 美子 京都府立医科大学, 医学(系)研究科(研究院), 助教 (30768825)
竹村 佳純 京都府立医科大学, 医学(系)研究科(研究院), 助教 (50434684)
|
|---|
| Research Collaborator |
TANIMURA KEIKO
|
|---|
| Project Period (FY) |
2016-04-01 – 2019-03-31
|
| Keywords | 肺癌 / 免疫チェックポイント阻害剤 / 効果予測因子 |
|---|
| Outline of Final Research Achievements |
The aim of this study is to finding the predictive marker for immune-checkpoint inhibitor in cancer treatment. Surgically resected lung cancer specimens were used to evaluate the tumor factors including p53, PD-L1 and VEGF. Also, tumor infiltrating lymphocytes (TIL) were calculated by image analyzer automatically. Cytotoxic T-lymphocyte and regulatory T-lymphocyte were identified by immunohistochemical staining by CD8 antibody and Foxp3 antibody, respectively. In result, TIL were not associated with p53 or VEGF expression. However, tumor PD-L1 expression is associated with Foxp3 positive T-lymphocyte, suggesting regulatory T-lymphocyte induction by PD-L1.
|
| Free Research Field |
呼吸器腫瘍
|
| Academic Significance and Societal Importance of the Research Achievements |
免疫チェックポイント阻害剤は現在肺癌だけでなく、多くの癌の治療に広く使用されている。その有効性を予測する因子としてPD-L1の発現が用いられているが、高発現例でも効果を全く認めない場合もあり、より正確なバイオマーカーが求められている。新規バイオマーカーが発見されれば、有効性が期待できる患者にのみ同薬剤を使用することで、無駄な治療を避けることができ、医療経済の効率化にもつながる。
|
